Investor Presentaiton

We are leveraging expertise to enable expansion beyond Hematology while increasing manufacturing efficiency Wave 1 Single CAR binder Wave 2 Dual CAR binder Wave 3 Multiple other KO/KI Dual CAR binder TCR KO Next-gen engineering MHC-I KO MHC-II KO Evolving delivery systems Optimizing manufacturing Monospecific CAR Surface GP200 Tran) MA (matrial Prote A p Dual Targeting CAR 3 VV NC nucleocap CA Lentivirus (LVV) Autologous Breyanzi Abecma a/B T cells Adeno-associated virus (AAV) Ill Bristol Myers Squibb™ 2 seventybio Arsenal Bio editas OBSIDIAN MEDICINE Autologous NEX T platform Engineered CAR/TCR electroporation MINIMIN DNA MIN MINIMIM Lipid nanoparticles (LNP) Non-viral delivery (NVD) Allogeneic Healthy donor or iPSC a/B or y/o T cells, iNK/iT cells a/B T cells gentibio① CENTURY Not for Product Promotional Use 44 THERAPEUTICS Immatics

View entire presentation